Scientific Background: Axitinib is a potent and selective tyrosine kinase inhibitor that blocks VEGF receptors 1, 2 and 3. It has also been shown to inhibit PDGFR-β and c-Kit.
References: 1. Hu-Lowe D.D., et al. (2008) Clin. Cancer Res: J. Am. Ass. Cancer Res. 14(22): 7272–7283.
Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.